149 related articles for article (PubMed ID: 21709691)
1. The impact of PSA testing frequency on prostate cancer incidence and treatment in older men.
Shao YH; Albertsen PC; Shih W; Roberts CB; Lu-Yao GL
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):332-9. PubMed ID: 21709691
[TBL] [Abstract][Full Text] [Related]
2. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
Zanwar P; Lin YL; Kuo YF; Goodwin JS
BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
[TBL] [Abstract][Full Text] [Related]
3. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
4. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.
Legler JM; Feuer EJ; Potosky AL; Merrill RM; Kramer BS
Cancer Causes Control; 1998 Oct; 9(5):519-27. PubMed ID: 9934717
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Welch HG; Albertsen PC
J Natl Cancer Inst; 2009 Oct; 101(19):1325-9. PubMed ID: 19720969
[TBL] [Abstract][Full Text] [Related]
6. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
7. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.
Loeb S; Walter D; Curnyn C; Gold HT; Lepor H; Makarov DV
J Urol; 2016 Sep; 196(3):721-6. PubMed ID: 26946161
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.
Etzioni R; Berry KM; Legler JM; Shaw P
Urology; 2002 Feb; 59(2):251-5. PubMed ID: 11834397
[TBL] [Abstract][Full Text] [Related]
9. Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly.
Hu JC; Williams SB; Carter SC; Eggener SE; Prasad S; Chamie K; Trinh QD; Sun M; Nguyen PL; Lipsitz SR
Urol Oncol; 2015 Feb; 33(2):69.e29-34. PubMed ID: 25017694
[TBL] [Abstract][Full Text] [Related]
10. Race and prostate specific antigen surveillance testing and monitoring 5-years after definitive therapy for localized prostate cancer.
Asiri IM; Chen RC; Young HN; Codling J; Mandawat A; Beach SRH; Master V; Rajbhandari-Thapa J; Cobran EK
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1093-1102. PubMed ID: 33941865
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?
Valberg M; Grotmol T; Tretli S; Veierød MB; Moger TA; Devesa SS; Aalen OO
Eur J Epidemiol; 2017 Jun; 32(6):511-520. PubMed ID: 27431530
[TBL] [Abstract][Full Text] [Related]
12. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml.
Shao YH; Albertsen PC; Roberts CB; Lin Y; Mehta AR; Stein MN; DiPaola RS; Lu-Yao GL
Arch Intern Med; 2010 Jul; 170(14):1256-61. PubMed ID: 20660846
[TBL] [Abstract][Full Text] [Related]
13. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
[TBL] [Abstract][Full Text] [Related]
14. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.
Howrey BT; Kuo YF; Lin YL; Goodwin JS
J Gerontol A Biol Sci Med Sci; 2013 Jan; 68(1):56-61. PubMed ID: 22562961
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen testing of older men.
Carter HB; Landis PK; Metter EJ; Fleisher LA; Pearson JD
J Natl Cancer Inst; 1999 Oct; 91(20):1733-7. PubMed ID: 10528023
[TBL] [Abstract][Full Text] [Related]
16. Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease.
Tosoian JJ; Alam R; Gergis C; Narang A; Radwan N; Robertson S; McNutt T; Ross AE; Song DY; DeWeese TL; Tran PT; Walsh PC
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):193-196. PubMed ID: 28045113
[TBL] [Abstract][Full Text] [Related]
17. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey.
Mariotto AB; Etzioni R; Krapcho M; Feuer EJ
Cancer; 2007 May; 109(9):1877-86. PubMed ID: 17372918
[TBL] [Abstract][Full Text] [Related]
18. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
19. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
20. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]